Efficacy of Combination of Topical Ketoconazole 2% Cream and Adapalene 0.1% Gel versus Topical Ketoconazole 2% Cream Alone in Treatment of Pityriasis Versicolor: Topical Ketoconazole and Adapalene for Pityriasis Versicolor Treatment

Faiza Munir; Erfan Khattak; Wasiq Zafar Abbasi; Sabeen Shakir; Sameer Ahmed; Amanat Ali

doi:10.54393/pjhs.v5i04.1395

Authors

Faiza Munir Department of Dermatology, Nishtar Hospital, Multan, Pakistan
Erfan Khattak Department of Dermatology, Akhtar Saeed Medical College, Rawalpindi, Pakistan
Wasiq Zafar Abbasi Department of Medicine, Abu-Amara Medical and Dental College, Lahore, Pakistan
Sabeen Shakir Department of Pharmacology, Akhtar Saeed Medical College, Rawalpindi, Pakistan
Sameer Ahmed Department of Pharmacology, Rawal Institute of Health Sciences, Rawalpindi, Pakistan
Amanat Ali Department of Pharmacology, HBS Medical and Dental College, Islamabad, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i04.1395

Keywords:

Adapalene, Efficacy, Ketoconazole 2%, Malassezia, Pityriasis Versicolor

Abstract

Pityriasis Versicolor (PV) is a superficial skin infection caused by Malassezia yeasts, resulting in hypo and hyperpigmented macules. It affects up to 40% of individuals, often leading to itching, decreased quality of life, and social stigma. Objective: To compare the efficacy of combination of topical ketoconazole 2% cream and adapalene 0.1% gel versus topical ketoconazole 2% cream alone in treatment of pityriasis versicolor. Methods: A comparative cross-sectional study was conducted at the Department of Dermatology, Nishtar Hospital, Multan, spanning from November 2020 to April 2021. Total 90 patients were divided equally into two groups: Group A received a combination of Ketoconazole 2% cream and adapalene 1% gel, while Group B received Ketoconazole 2% cream alone. The efficacy of both treatments was evaluated and compared. The study utilized SPSS version 26.0 for data analysis. Results: In terms of gender, 52.22% were male, and 47.78% were female across both groups. The mean duration of the disease was 5.84 ± 3.26 years in Group A and 6.04 ± 3.11 years in Group B, with an overall mean of 5.95 ± 3.17 years. The efficacy of Group A was 91.11%, with 41 participants showing positive results, while Group B had an efficacy of 75.56%, with 34 participants showing positive results. Conclusions: The study findings indicate that using a combination of adapalene 0.1% gel and ketoconazole 2% cream is more efficacious than using ketoconazole 2% cream alone in treating PV

References

Vishwanath T, Kapadia FM, Mahajan SA, Kharkar VD, Chikhalkar SB, Gole PV et al. Dermoscopic Perspective of Pityriasis Versicolor in a Cross-Sectional Study. Indian Dermatology Online Journal. 2024 Mar; 15(2): 218-25. doi: 0.4103/idoj.idoj_319_23. DOI: https://doi.org/10.4103/idoj.idoj_319_23

KK A, Vineetha M, MI C. Clinicomycological study of pityriasis versicolor. Asian Journal of Medical Sciences. 2022 Jun; 13(6). doi: 10.3126/ajms.v13i6.42383. DOI: https://doi.org/10.3126/ajms.v13i6.42383

Tilaye M, Sinknew A, Mekuriaw A, Tsehay AK. Magnitude and associated factors of Pityriasis Versicolor among patients attending Dermatovenereology Outpatient Department at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia. Journal of Current Health Sciences. 2023 May; 3(1): 31-8. doi: 10.47679/jchs.202346. DOI: https://doi.org/10.47679/jchs.202346

Nguyen BD, Vo HT, Thanh MD, Van Vu T, Lai TT, Nguyen MT et al. Epidemiological characterization of pityriasis versicolor and distribution of Malassezia species among students in Hai Phong city, Vietnam. Current Medical Mycology. 2020 Jun; 6(2) :11. doi: 10.18502/cmm.6.2.2838. DOI: https://doi.org/10.18502/cmm.6.2.2838

Chebil W, Rhimi W, Haouas N, Romano V, Belgacem S, Belhadj Ali H et al. Virulence factors of Malassezia strains isolated from pityriasis versicolor patients and healthy individuals. Medical Mycology. 2022 Aug; 60(8): myac060. doi: 10.1093/mmy/myac060. DOI: https://doi.org/10.1093/mmy/myac060

Wang K, Cheng L, Li W, Jiang H, Zhang X, Liu S et al. Susceptibilities of Malassezia strains from pityriasis versicolor, Malassezia folliculitis and seborrheic dermatitis to antifungal drugs. Heliyon. 2020 Jun; 6(6). doi: 10.1016/j.heliyon.2020.e04203. DOI: https://doi.org/10.1016/j.heliyon.2020.e04203

Chang YM and Wu PY. Atrophying pityriasis versicolor: A rare variant with review of literature. Dermatologica Sinica. 2021 Apr; 39(2): 83-4. doi: 10.4103/ds.ds_3_21. DOI: https://doi.org/10.4103/ds.ds_3_21

Łabędź N, Navarrete-Dechent C, Kubisiak-Rzepczyk H, Bowszyc-Dmochowska M, Pogorzelska-Antkowiak A, Pietkiewicz P. Pityriasis versicolor—a narrative review on the diagnosis and management. Life. 2023 Oct; 13(10): 2097. doi: 10.3390/life13102097. DOI: https://doi.org/10.3390/life13102097

Ismail BA, Fatima SH, Nawab M. The Current Understanding of the Clinical Condition Bahaq (Pityriasis Versicolor)–Hypothesis and A Review of Evidences. Traditional and Integrative Medicine. 2021 Sep: 249-58.

Bansal L and Dhiman A. A brief review of fungal infection-pityriasis versicolor. EAS Journal of Medicine and Surgery. 2022; 4: 19-23. doi: 10.36349/easjms.2022.v04i01.004. DOI: https://doi.org/10.36349/easjms.2022.v04i01.004

Saunte DM, Gaitanis G, Hay RJ. Malassezia-associated skin diseases, the use of diagnostics and treatment. Frontiers in Cellular and Infection Microbiology. 2020 Mar; 10: 112. doi: 10.3389/fcimb.2020.00112. DOI: https://doi.org/10.3389/fcimb.2020.00112

Hameed S, Paracha MM, Sagheer F, Khan AQ, Noor SM. Comparative study of efficacy of combined treatment with ketoconazole 2% cream and adapalene 0.1% gel vs. Ketoconazole 2% cream monotherapy in pityriasis versicolor. American Journal of Health, Medicine and Nursing Practice. 2022 May; 7(6): 33-40. doi: 10.47672/ajhmn.1029. DOI: https://doi.org/10.47672/ajhmn.1029

Ashraf S. Comparison of topical ketoconzole alone versus topical ketoconazole plus topical adapalene in the treatment of patients with pityriasis versicolor. MedERA-Journal of CMH LMC and IOD. 2018; 2.

Khan MM, Noor SM, Nawaz K. Single dose fluconazole in the treatment of pityriasis versicolor. Journal of Pakistan Association of Dermatologists. 2007; 17(1): 28-31.

Wahid Z, Nasreen S, Usman G, Ahmed I. Frequency of pityriasis versicolor in patients with uncontrolled type 2 diabetes attending a tertiary care hospital. Journal of Liaquat University of Medical and Health Sciences. 2013 Jan; 12(01): 03.

Tawfik KM, Mahmmoud WA, Ali AG. Ketoconazole 2% cream versus a combination of ketoconazole 2% cream and adapalene 0.1% gel in the treatment of pityriasis versicolor. Al-Azhar Assiut Medical Journal. 2022 Jan; 20(1): 100-3. DOI: https://doi.org/10.4103/azmj.azmj_97_21

Shi TW, Zhang JA, Tang YB, Yu HX, Li ZG, Yu JB. A randomized controlled trial of combination treatment with ketoconazole 2% cream and adapalene 0.1% gel in pityriasis versicolor. Journal of Dermatological Treatment. 2015 Mar; 26(2): 143-6. doi: 10.3109/09546634.2014.921661. DOI: https://doi.org/10.3109/09546634.2014.921661

Anwar A, Raza N, Ahmed N, Awan HA. Comparison of efficacy of combination of 2% ketoconazole solution wash and topical 1% clotrimazole with topical 1% clotrimazole alone in c. Pakistan Armed Forces Medical Journal. 2018 Dec; 68(6): 1725-30.

Gobbato AA, Babadópulos T, Gobbato CA, Ilha JD, Gagliano-Jucá T, De Nucci G. A randomized double-blind, non-inferiority Phase II trial, comparing dapaconazole tosylate 2% cream with ketoconazole 2% cream in the treatment of Pityriasis versicolor. Expert Opinion on Investigational Drugs. 2015 Nov; 24(11): 1399-407. doi: 10.1517/13543784.2015.1083009. DOI: https://doi.org/10.1517/13543784.2015.1083009

Bakr E, Abdo H, Abd‐Elaziz H, Abd‐Elrazek H, Amer M. Adapalene gel 0.1% vs ketoconazole cream 2% and their combination in treatment of pityriasis versicolor: A randomized clinical study. Dermatologic Therapy. 2020 May; 33(3): e13319. doi: 10.1111/dth.13319. DOI: https://doi.org/10.1111/dth.13319